Jones Trading analyst Debanjana Chatterjee initiates coverage on AbCellera Biologics (NASDAQ: ABCL) with a Buy rating and a price target of $11.00.

For an analyst ratings summary and ratings history on AbCellera Biologics click here. For more ratings news on AbCellera Biologics click here.

Shares of AbCellera Biologics closed at $3.43 yesterday.